Clinical Trial to Evaluate the Efficacy and Safety of YHP1701

Yuhan Corporation106 enrolled

Overview

The purpose of this study is to determine superiority of YHP1701 comparing to each monotherapy in patient with hypertension and primary hypercholesterolemia.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

106

Conditions

Hypertension and Hyperlipidemia

Interventions

YHP1701DRUG

PO, Once daily (QD), 8 weeks

YHR1703DRUG

PO, Once daily (QD), 8 weeks

YHR1704DRUG

PO, Once daily (QD), 8 weeks

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Both man and woman who is over 19 years old * Patient with dyslipidemia and hypertension Exclusion Criteria: * sSBP difference is ≥20 mmHg or sDBP difference is ≥10 mmHg * A history of cardiovascular disease * Rhabdomyolysis, myopathy * Hypertension or hypercholesterolemia due to secondary causes * Uncontrolled diabetes * Evidence of hepatic or renal disease

Locations (1)

Seoul Medical Center

Seoul, South Korea

Outcomes

Primary Outcomes

Percent change of LDL-Cholesterol

LDL-Cholesterol

Time frame: 0, 8 weeks

Change of mean seated Systolic Blood Pressure

Blood Pressure

Time frame: 0, 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.